Canaccord lowered the firm’s price target on Hinge Health (HNGE) to $53 from $65 and keeps a Buy rating on the shares. The firm said the comopany delivered a strong 4Q’25 upside that beat estimates and guidance, and providing a 1Q’26 and annual outlook that was better than anticipated. Hinge has significant room to continue growing and delivering strong financial results, leading to further upward estimate revisions. Guidance contemplates stable pricing and flat yield.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health: Strong Beat, Operating Leverage, and Cash Generation Create an Attractive Long‑Term Buy After Share Pullback
- Hinge Health Posts Record 2025 Results With Strong Profitability
- Hinge Health reports Q4 EPS 49c, consensus 43c
- Hinge Health sees Q1 revenue $171M-$173M, consensus $159.67M
- Hinge Health sees Fy26 revenue $732M-$742M, consensus $700.41M